ICAAC 2015: Merck's Bezlotoxumab A 'Big Step' In C Diff
This article was originally published in Scrip
Executive Summary
Merck & Co.'s bezlotoxumab for the treatment of recurrent clostridium difficile (C diff) infections is "a big step" for treatment of the debilitating and potentially deadly gut infection, according to Dale Gerding, a professor at Loyola University Chicago Stritch School of Medicine and a lead investigator for the monoclonal antibody's Phase III clinical trials.